1 In addition, the ultimate benefits of spending on ART depend on the choices concerning drugs, technology, and care of patients that can alter its cost effectiveness profile.
Our findings show that both rotavirus and HPV vaccines have potential to reduce mortality and be cost-effective investments in GAVI country settings, with very similar cost-effectiveness profiles in terms of cost per DALY averted.
Antiresorptive agents are considered effective in reducing fracture incidence and generally have favorable cost-effectiveness profiles for most postmenopausal women with osteoporosis.
Antiresorptive agents are considered effective in reducing the incidence of fracture and have favorable cost-effectiveness profiles for most postmenopausal women with osteoporosis[ 40].
All variant scenarios had favourable cost-effectiveness profiles compared with no screening.
Except for three outlier countries (Cuba, Moldova, and Ukraine) cost-effectiveness profiles of the two vaccines were very similar.
This study evaluates the cost-effectiveness profiles of these two regimens in comparison to standard chemotherapy, using evidence from two international randomised controlled trials.
Additionally, the cost-effectiveness profiles derived for individual vaccines from separate studies make for problematic comparison, as the analyses use different data sources and assumptions.
Although the vaccine against HPV increases the cost of preventing cervical cancer, this new preventive technology presents favorable cost-effectiveness profiles in the case of Brazil.
The cost-effectiveness profiles of rotavirus vaccines from the present study are also very similar to those for HPV vaccines reported in a previous study [ 60], which was performed using a similar approach in the 72 GAVI-eligible countries.
All three scenarios appeared to have favourable cost-effectiveness profiles when compared marginally against no screening (i.e. the ICER was significantly lower than the notional cost-effectiveness threshold of €45 000 per QALY).
